SAN DIEGO, July 27, 2021 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the second quarter 2021 on Monday, August 9 at 4:30
p.m. ET / 1:30 p.m. PT. Dr.
Helen Torley, president and chief
executive officer, will lead the call. On the same date, Halozyme
will release financial results for the second quarter ended
June 30, 2021 following the close of
trading.
To register for this conference call, please use this link:
http://www.directeventreg.com/registration/event/5694076. After
registering, you will receive an email confirmation that includes
dial in details and unique conference call codes for entry.
Registration is open through the live call. However, to ensure you
are connected for the full call, we suggest registering a day in
advance or at minimum 10 minutes before the start of the call.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit the
Investors page of www.halozyme.com approximately 15
minutes prior to the call to register, download and install any
necessary audio software. A telephone replay will be available for
two weeks after the call by dialing (800) 585-8367 (domestic
callers) or (416) 621-4642 (international callers) using replay ID
number 5694076.
About Halozyme
Halozyme is a biopharmaceutical
company bringing disruptive solutions to significantly improve
patient experiences and outcomes for emerging and established
therapies. Halozyme advises and supports its biopharmaceutical
partners in key aspects of new drug development with the goal of
improving patients' lives while helping its partners achieve global
commercial success. As the innovators of the ENHANZE®
technology, which can reduce hours-long treatments to a matter of
minutes, Halozyme's commercially-validated solution has touched
more than 500,000 patient lives via five commercialized products
across more than 100 global markets. Halozyme and its world-class
partners are currently advancing multiple therapeutic programs
intended to deliver innovative therapies, with the potential to
improve the lives of patients around the globe. Halozyme's
proprietary enzyme rHuPH20 forms the basis of the
ENHANZE® technology and is used to facilitate the
delivery of injected drugs and fluids, potentially reducing the
treatment burden of other drugs to patients. Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon
Therapeutics and ViiV Healthcare. Halozyme derives revenues from
these collaborations in the form of milestones and royalties as the
Company's partners make progress developing and commercializing
their products being developed with ENHANZE®. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate
Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-host-second-quarter-2021-financial-results-webcast-and-conference-call-301342529.html
SOURCE Halozyme Therapeutics, Inc.